All In Biotech

Drug Trial Radar · NCT07596784

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

An Open-label, Single-arm, Multi-center, Interventional Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adult Patients With Generalized Myasthenia Gravis (gMG)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Aug 24, 2027

Study completion Aug 24, 2027

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).

Conditions

  • Generalized Myasthenia Gravis
  • gMG

Interventions

  • RavulizumabDrug

    Participants will receive ravulizumab via intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) Total Score at Week 26Time frame: Baseline, Week 26

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Changchun, China · Not yet recruiting

  • Research Site

    Fuzhou, China · Recruiting

  • Research Site

    Jinan, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shijiazhuang, China · Recruiting

  • Research Site

    Taiyuan, China · Recruiting

  • Research Site

    Tianjin, China · Recruiting

  • Research Site

    Wuhan, China · Not yet recruiting

  • Research Site

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.